Advantage and clinical prospect of combining Chinese and western medicine in preventing and treating tumor recurrence and metastasis

Haoze LI; Jing ZHOU; Qi LI; Qing JI

doi:10.16305/j.1007-1334.2022.2108125

您当前的位置：

首页 >

文章列表页 >

Advantage and clinical prospect of combining Chinese and western medicine in preventing and treating tumor recurrence and metastasis

更新时间：2022-07-10

- Advantage and clinical prospect of combining Chinese and western medicine in preventing and treating tumor recurrence and metastasis
- Shanghai Journal of Traditional Chinese Medicine Vol. 56, Issue 2, Pages: 91-95(2022)
- 作者机构：
  
  1.上海中医药大学附属曙光医院肿瘤科/肿瘤研究所（上海 201203）
  2.上海中医药大学中西医结合研究院（上海 201203）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2022.2108125
  CLC：
扫描看全文
李昊泽,周晶,李琦等.中西医结合疗法防治肿瘤复发转移的优势及展望[J].上海中医药杂志,2022,56(02):91-95.

LI Haoze,ZHOU Jing,LI Qi,et al.Advantage and clinical prospect of combining Chinese and western medicine in preventing and treating tumor recurrence and metastasis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):91-95.
李昊泽,周晶,李琦等.中西医结合疗法防治肿瘤复发转移的优势及展望[J].上海中医药杂志,2022,56(02):91-95. DOI： 10.16305/j.1007-1334.2022.2108125.

LI Haoze,ZHOU Jing,LI Qi,et al.Advantage and clinical prospect of combining Chinese and western medicine in preventing and treating tumor recurrence and metastasis[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):91-95. DOI： 10.16305/j.1007-1334.2022.2108125.

摘要

探讨中西医结合疗法防治肿瘤复发转移的优势及潜在前景。分析单一疗法防治肿瘤复发转移的优势和局限性及中西医结合防治肿瘤复发转移的优势，认为中医药联合化疗、靶向疗法、化疗和靶向结合疗法、免疫治疗均优于单一疗法，不仅可明显改善药物副反应，提高患者生活质量，更重要的是能防治肿瘤的复发转移，延长患者无进展生存期及总生存期。

Abstract

The purpose of this paper is to explore the advantages and potential prospects of combined therapy of Chinese and western medicine in the prevention and treatment of tumor recurrence and metastasis based on the analysis of the advantages and limitations of monotherapy in the prevention and treatment of tumor recurrence and metastasis as well as the advantages of combination of traditional Chinese and western medicine in the prevention and treatment of tumor recurrence and metastasis. It is concluded that traditional Chinese medicine combined with chemotherapy， targeted therapy， chemotherapy and targeted combination therapy and immunotherapy are superior to monotherapy， which can not only significantly decrease the drug side effects and improve the quality of life， but also more importantly prevent recurrence and metastasis and prolong the progression-free survival and overall survival of patients.

关键词

肿瘤复发转移中医学西医学中西医结合疗法综述

Keywords

tumorrecurrence and metastasisChinese medicinewestern medicineintegrated Chinese and western medicine treatmentreview

references

Global Burden of Disease Cancer Collaboration， FITZMAURICE C， ABATE D， et al. Global， regional， and national cancer incidence， mortality， years of life lost， years lived with disability， and disability-adjusted life-years for 29 cancer groups， 1990 to 2017： a systematic analysis for the global burden of disease study［J］. JAMA Oncol， 2019， 5（12）： 1749-1768.

HANAHAN D， WEINBERG R. Hallmarks of cancer： the next generation［J］. Cell， 2011， 144（5）： 646-74.

DILLEKÅS H， ROGERS M S， STRAUME O. Are 90% of deaths from cancer caused by metastases？［J］. Cancer Med， 2019， 8（12）： 5574-5576.

邱培，郑希，谭小波，等. 非小细胞肺癌患者微创切除术后复发与转移的相关因素分析［J］. 实用癌症杂志，2020， 35（4）： 598-602.

MOMMA T， HAMBLIN M R， WU H C， et al. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative： local control and distant metastasis［J］. Cancer Res， 1998， 58（23）： 5425-5431.

GOLDFARB Y， BEN-ELIYAHU S. Surgery as a risk factor for breast cancer recurrence and metastasis： mediating mechanisms and clinical prophylactic approaches［J/OL］. Breast Dis， 2006［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/17473369/https://pubmed.ncbi.nlm.nih.gov/17473369/.

Early Breast Cancer Trialists' Collaborative Group（EBCTCG）， DARBY S， MCGALE P， et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death： meta-analysis of individual patient data for 10，801 women in 17 randomised trials［J］. Lancet， 2011， 378（9804）： 1707-1716.

YU J J， XIAO W， DONG S L， et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma［J］. BMC Cancer， 2018， 18（1）： 835.

罗秋月，张青，熊绍权，等. 化疗促肿瘤转移的机制研究［J］. 医学研究生学报，2019， 32（3）： 307-312.

VOLK-DRAPER L， HALL K， GRIGGS C， et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner［J］. Cancer Res， 2014， 74（19）： 5421-5434.

ZIGLER M， SHIR A， LEVITZKI A. Targeted cancer immunotherapy［J］. Curr Opin in Pharmacol， 2013， 13（4）： 504-510.

孙旭，郑玉玲，刘怀民. 中医药在食管癌免疫治疗中的研究与思考［J］. 中医肿瘤学杂志，2020， 2（3）： 10-14，30.

KENNEDY L B， SALAMA A K S. A review of cancer immunotherapy toxicity［J］. CA Cancer J Clin， 2020， 70（2）： 86-104.

MATHIAS T J， CHANG K T， MARTIN S S， et al. Gauging the impact of cancer treatment modalities on circulating tumor cells（CTCs）［J］. Cancers（Basel）， 2020， 12（3）： 743.

MCQUADE J L， MENG Z Q， CHEN Z， et al. Utilization of and attitudes towards traditional Chinese medicine therapies in a Chinese cancer hospital： a survey of patients and physicians［J/OL］. Evid Based Complement Alternat Med， 2012［2121-07-10］. https：//pubmed.ncbi.nlm.nih.gov/23093982/https://pubmed.ncbi.nlm.nih.gov/23093982/.

刘宣，周利红，隋华，等. 健脾解毒方对大肠癌细胞COX-2/β-catenin/MMP-7信号通路的影响［J］. 上海中医药杂志，2016， 50（4）： 65-69.

LI L， WANG S， YANG X， et al. Traditional Chinese medicine， fuzheng kang‑ai decoction， inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway［J］. Mol Med Rep， 2017， 16（3）： 2461-2468.

ZENG Q， CHE Y， ZHANG Y， et al. Thymol isolated from thymus vulgaris l. inhibits colorectal cancer cell growth and metastasis by suppressing the wnt/β-catenin pathway［J/OL］. Drug Des Devel Ther， 2020［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/32669835/https://pubmed.ncbi.nlm.nih.gov/32669835/.

侯文珍，裴丽霞，周锦勇，等. 中医药防治大肠癌肝转移研究进展［J］. 辽宁中医杂志，2020， 47（3）： 203-206.

LIN S， AN X， GUO Y， et al. Meta-analysis of astragalus-containing traditional Chinese medicine combined with chemotherapy for colorectal cancer： efficacy and safety to tumor response［J/OL］. Front Oncol， 2019［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/31456940/https://pubmed.ncbi.nlm.nih.gov/31456940/.

唐德才. 活血化瘀药在抗肿瘤及转移中的运用思考［J］. 南京中医药大学学报，2019， 35（1）： 1-4.

方锦舒，王祥，朱宝龙. 培土固本方对进展期胃癌患者术后生存质量的影响［J］. 中医学报，2016， 31（9）： 1258-1261.

胡志辉. 复方斑蝥胶囊联合XELOX方案对胃癌术后血清转移相关指标水平和T淋巴细胞亚群的影响［J］. 中医学报，2018， 33（4）： 536-540.

徐萌，王勇，张梅，等. Ⅲ期结肠癌术后辅助化疗联合中药治疗的疗效研究［J］. 安徽医学，2020， 41（3）： 273-276.

李华. 中药活血化瘀在防治恶性肿瘤术后复发与转移中的应用效果［J］. 黑龙江中医药，2020， 49（2）： 118-119.

ZHAO X Y， DAI X J， WANG S S， et al. Traditional Chinese medicine integrated with chemotherapy for stage II-IIIA patients with non-small-cell lung cancer after radical surgery： a retrospective clinical analysis with small sample size［J/OL］. Evid Based Complement Alternat Med， 2018［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/30147731/https://pubmed.ncbi.nlm.nih.gov/30147731/.

ZHAO L， ZHAO A G， ZHA G， et al. Survival benefit of traditional Chinese herbal medicine（a herbal formula for invigorating spleen） in gastric cancer patients with peritoneal metastasis［J/OL］. Evid Based Complement Alternat Med， 2014［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/24723961/https://pubmed.ncbi.nlm.nih.gov/24723961/.

XU Y， MAO J J， SUN L， et al. Association between use of traditional Chinese medicine herbal therapy and survival outcomes in patients with stage Ⅱ and Ⅲ colorectal cancer： a multicenter prospective cohort study［J/OL］. J Natl Cancer Inst Monogr， 2017［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/29140496/https://pubmed.ncbi.nlm.nih.gov/29140496/.

曹子丰，唐德才，时晓霞，等. 黄芪、莪术配伍联合奥沙利铂对CT26.WT原位移植瘤小鼠中CXCR3、CCR6表达影响［J］. 北京中医药大学学报，2017， 40（6）： 477-482.

蒋海燕，张士强，杨蕴，等. 基于“肺与大肠相表里”研究健脾固肠方通过调节肠道免疫平衡抑制肺癌小鼠肿瘤转移的机制［J］. 上海中医药杂志，2020， 54（3）： 91-96.

付淑娟，周张杰，吴婷婷，等. 扶正健脾方联合化疗通过PI3K/AKT信号通路对肿瘤转移微环境的影响［J］. 中医学报，2019， 34（4）： 766-770.

JIAO L， XU J， SUN J， et al. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma（CATLA）： a multicenter， randomized， double-blind， placebo-controlled trial［J/OL］. Front Pharmacol， 2019［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/31333456/https://pubmed.ncbi.nlm.nih.gov/31333456/.

冯原，陈斯宁，江颖，等. 补肺化瘀汤联合吉非替尼治疗EGFR突变型晚期非小细胞肺癌［J］. 中国老年学杂志，2019， 39（23）： 5682-5686.

赵良辰，李陆振，袁锦辉，等. 六君子汤加减联合吉非替尼片治疗晚期脾虚痰湿型非小细胞肺癌的临床研究［J］. 广州中医药大学学报，2021， 38（2）： 250-256.

张莹瑄，任建琳，吴杏黎，等. 散结抑癌方联合贝伐珠单抗对BALB/c裸鼠结肠癌肺转移的影响［J］. 国际消化病杂志，2021， 41（3）： 200-204， 229.

YANG Y， SUN M， YAO W， et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib［J/OL］. J Immunother Cancer， 2020［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/32179631/https://pubmed.ncbi.nlm.nih.gov/32179631/.

XIE W， ZHANG Y， ZHANG S， et al. Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway［J］. Am J Cancer Res， 2019， 9（8）： 1796-1814.

李珍，颜艳艳，许潜，等. 中药归经于脾胃与精准医学靶向治疗理念相关性思考［J］. 中国现代医生，2019， 57（36）： 116-119.

陶倩逸. 健脾化痰方联合TA方案治疗晚期胃癌的临床疗效评价及其抗转移机制作用研究［D］. 南京：南京中医药大学，2019： 51.

LIU N， WU C， JIA R， et al. Traditional Chinese medicine combined with chemotherapy and cetuximab or bevacizumab for metastatic colorectal cancer： a randomized， double-blind， placebo-controlled clinical trial［J/OL］. Front Pharmacol， 2020［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/32372960/https://pubmed.ncbi.nlm.nih.gov/32372960/.

王斌，田华琴，王艳杰，等. 四虫散联合鸦胆子油乳治疗非小细胞肺癌脑转移临床研究［J］. 中医学报，2016， 31（1）： 8-11.

RIBAS A， WOLCHOK J D. Cancer immunotherapy using checkpoint blockade［J］. Science， 2018， 359（6382）： 1350-1355.

WANG Y， ZHANG Q， CHEN Y， et al. Antitumor effects of immunity-enhancing traditional Chinese medicine［J/OL］. Biomed Pharmacother， 2020［2021-07-10］. https：//pubmed.ncbi.nlm.nih.gov/31710893/https://pubmed.ncbi.nlm.nih.gov/31710893/.

LV J， JIA Y， LI J， et al. Gegen qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment［J］. Cell Death Dis， 2019， 10（6）： 415.

刘群英，张博，李海燕，等. 消瘰丸治疗淋巴瘤基于PD-1/PD-L1信号通路的机制研究［J］. 天津中医药，2018， 35（5）： 370-375.

郭奕维，郭秀臣，张静波，等. 人参皂苷Rg3增强PD-1抑制剂对弥漫大B细胞淋巴瘤免疫治疗作用的体外研究［J］. 中医药学报，2018， 46（5）： 24-29.

LI X， XU P， WANG C， et al. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma［J］. Oncotarget， 2017， 8（13）： 21177-21186.

HAO H， ZHANG Q， ZHU H， et al. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice［J］. Eur J Immunol， 2019， 49（12）： 2235-2244.

PAGET G. Remarks on a case of alternate partial anaesthesia［J］. Br Med J， 1889， 1（1462）： 1-3.

SCENEAY J， SMYTH MARK J， MÖLLER A. The pre-metastatic niche： finding common ground［J］. Cancer Metastasis Rev， 2013， 32（3-4）： 449-464.

WANG J， TIAN L， KHAN M， et al. Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness［J］. Cancer Lett， 2018（415）： 73-85.

WANG H， ZHANG C， CHI H， et al. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling［J］. Int J Oncol， 2018， 52（6）： 2051-2060.

SHENG X， SUN X， SUN K， et al. Inhibitory effect of bufalin combined with Hedgehog signaling pathway inhibitors on proliferation and invasion and metastasis of liver cancer cells［J］. Int J Oncol， 2016， 49（4）： 1513-1524.

田建辉，罗斌，阙祖俊，等. 癌症转移亚临床阶段核心病机“正虚伏毒”学说［J］. 上海中医药杂志，2021， 55（10）： 1-3，13.

王亚斌. 中西医结合综合治疗法在中晚期癌症中的临床运用［J］. 中医临床研究，2019， 11（32）： 104-108.

Views

688

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress on myeloid-derived suppressor cells mediating tumor immune microenvironment remodeling and targeted therapy

Mechanism of Fructus Brucea against cancer

Research progress on anti-tumor mechanisms of icaritin and its related derivatives

Research progress on antitumor mechanism of curcumin

Research progress on anti-angiogenic effects of traditional Chinese medicine in tumor diseases

Related Author

No data

Related Institution

Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine

Institute of Traditional Chinese Medicine in Oncology,Department of Oncology,Longhua Hospital,Shanghai University of Traditional Chinese Medicine

Department of Urology,Huashan Hospital Affiliated to Fudan University

Department of Gastroenterology,Jinshan Hospital Affiliated to Fudan University

Department of Pharmacy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰